Stoppel Laura was awarded 16,250 derivative securities of Artiva Biotherapeutics on 2026-09-10. The award equals 100.0% of the resulting derivative-securities holding, giving investors a clear picture of the insider’s post-transaction position and the transaction’s full relationship to that holding.

Key Highlights

  • The transaction occurred on 10 September 2026.
  • The filing identifies the transaction with SEC transaction code A.
  • The award represented about 100.0% of Stoppel Laura’s resulting derivative-securities holding.

Award Recorded Under Transaction Code A

The award was recorded on 10 September 2026 under transaction code A. Stoppel Laura’s post-transaction position was 16,250 derivative securities, matching the amount awarded. Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) is the named company connected with the transaction. Stoppel Laura’s transaction represented about 100.0% of the resulting derivative-securities holding. Transaction code A denotes an award, grant, or other Acquisition from the company.